NYSE:BIO.B - Bio-Rad Laboratories Stock Price, News, & Analysis

Bio-Rad Laboratories, Inc. develops, manufactures, and markets products and solutions for the life science research and clinical diagnostic markets in Europe, the Pacific Rim, the United States, and internationally. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. It operates through two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cell biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, transfusion laboratories, and insurance and forensic testing laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.

Bio-Rad Laboratories (NYSE:BIO.B) Frequently Asked Questions

What is Bio-Rad Laboratories' stock symbol?

Bio-Rad Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "BIO.B."

When is Bio-Rad Laboratories' next earnings date?

Bio-Rad Laboratories is scheduled to release their next quarterly earnings announcement on Thursday, February 28th 2019. View Earnings Estimates for Bio-Rad Laboratories.

Has Bio-Rad Laboratories been receiving favorable news coverage?

Media stories about BIO.B stock have trended negative this week, InfoTrie reports. InfoTrie ranks the sentiment of news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Bio-Rad Laboratories earned a coverage optimism score of -2.1 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 1.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the immediate future.

Who are some of Bio-Rad Laboratories' key competitors?

Some companies that are related to Bio-Rad Laboratories include Agilent Technologies (A), Waters (WAT), Mettler-Toledo International (MTD), PerkinElmer (PKI), Bio-Rad Laboratories (BIO), Bruker (BRKR), Coherent (COHR), Horiba (HRIBF), Accelerate Diagnostics (AXDX), Pacific Biosciences of California (PACB), Quanterix (QTRX), Fluidigm (FLDM), Eyepoint Pharmaceuticals (EYPT), Harvard Bioscience (HBIO) and HTG Molecular Diagnostics (HTGM).

What other stocks do shareholders of Bio-Rad Laboratories own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bio-Rad Laboratories investors own include Accelerate Diagnostics (AXDX), NVIDIA (NVDA), Newell Brands (NWL), GRIFOLS S A/S (GRFS), Aptose Biosciences (APTO), Gamma Communications (GAMA), United Rentals (URI), Deluxe (DLX), Netflix (NFLX) and New Gold (NGD).

Who are Bio-Rad Laboratories' key executives?

Bio-Rad Laboratories' management team includes the folowing people:

• Mr. Norman D. Schwartz, Chairman, CEO & Pres (Age 69)
• Ms. Christine A. Tsingos, Exec. VP & CFO (Age 60)
• Mr. John Goetz, Consultant (Age 69)
• Mr. John Hertia, Exec. VP & Pres of Clinical Diagnostics Group (Age 63)
• Mr. Michael Crowley, Exec. VP of Global Commercial Operations (Age 57)

How do I buy shares of Bio-Rad Laboratories?

Shares of BIO.B can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Bio-Rad Laboratories' stock price today?

One share of BIO.B stock can currently be purchased for approximately $258.60.

How big of a company is Bio-Rad Laboratories?

Bio-Rad Laboratories has a market capitalization of $7.75 billion and generates $2.16 billion in revenue each year.

What is Bio-Rad Laboratories' official website?

The official website for Bio-Rad Laboratories is http://www.bio-rad.com.

How can I contact Bio-Rad Laboratories?

Bio-Rad Laboratories' mailing address is 1000 ALFRED NOBEL DR, HERCULES CA, . The company can be reached via phone at 510-724-7000 or via email at [email protected]